Literature DB >> 10504057

Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin.

R K Singh1, M L Varney, C D Bucana, S L Johansson.   

Abstract

It was recently demonstrated that interleukin-8 (IL-8) is produced by cultured melanoma cells and acts as an essential autocrine growth factor. Earlier studies from our laboratory demonstrated a direct correlation between IL-8 expression in human variant cell lines and their metastatic potential in nude mice. In the present study we examined the expression of IL-8 in human malignant melanomas using immunohistochemistry to correlate IL-8 levels with disease stage. None of the radial growth phase (RGP) tumours (melanoma in situ) expressed IL-8. In contrast, 50% of the vertical growth phase (VGP) tumours (invasive melanoma), which have a high risk of metastasis, showed IL-8 immunoreactivity. Further, all the metastatic lesions analysed showed intense staining for IL-8; the levels were higher than those observed in the primary skin tumours. In summary, the data suggest an association between the expression of IL-8 and the metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504057     DOI: 10.1097/00008390-199908000-00007

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  24 in total

1.  Shear stress and shear rate differentially affect the multi-step process of leukocyte-facilitated melanoma adhesion.

Authors:  Shile Liang; Margaret J Slattery; Cheng Dong
Journal:  Exp Cell Res       Date:  2005-09-09       Impact factor: 3.905

Review 2.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 3.  CXCL8 and its cognate receptors in melanoma progression and metastasis.

Authors:  Seema Singh; Ajay P Singh; Bhawna Sharma; Laurie B Owen; Rakesh K Singh
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

Review 4.  Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.

Authors:  Bhawna Sharma; Seema Singh; Michelle L Varney; Rakesh K Singh
Journal:  Expert Opin Ther Targets       Date:  2010-04       Impact factor: 6.902

5.  Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors.

Authors:  A S Haqqani; J K Sandhu; H C Birnboim
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

6.  Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype.

Authors:  Aihua Li; Michelle L Varney; Rakesh K Singh
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.

Authors:  Suyun Huang; Lisa Mills; Badar Mian; Carmen Tellez; Marya McCarty; X-D Yang; Jean M Gudas; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

8.  CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells.

Authors:  Yukiko Ueda; Yingjun Su; Ann Richmond
Journal:  Melanoma Res       Date:  2007-04       Impact factor: 3.599

9.  Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Sandra Pfeil; Mathias Wagner; Otto Kollmar; Berit Kopp; Stefan Graber; Bettina M Rau; Martin K Schilling
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

10.  Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.

Authors:  Michelle L Varney; Aihua Li; Bhavana J Dave; Corazan D Bucana; Sonny L Johansson; Rakesh K Singh
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.